Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, September 28, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced findings from two Real-World Evidence (RWE) studies and a qualitative sleep survey that underscore the prevalence of...
TOKYO and PITTSBURGH, PA, September 24, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and University of Pittsburgh (Chancellor: Patrick Gallagher, Ph.D., “Pittsburgh”) have entered into a research collaboration...
TOKYO, September 23, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) has signed an agreement with two research centers at the University of Tokyo (President: Makoto Gonokami, Ph.D.): The Institute for Life Science...
TOKYO and BOTHELL, Wash. -- September 18, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV® (enfortumab vedotin-ejfv)...
TOKYO, August 24, 2020 - Astellas Pharma Inc. (Tokyo, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it will start accepting advance applications and taking reservations for its exercise support service Fit-eNce®1, which encourages...
Follow us
